ENRIGHT PATRICK G 4

What Happened Patrick G. Enright, a director of Zenas BioPharma (ZBIO), received a derivative award (an option) covering 18,500 shares on June 15, 2026. The Form 4 reports the grant with a reported price of $0.00 (the filing shows an awarded option rather than an open-market purchase or sale). No cash changed hands at grant.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
• Instrument: Derivative—option award for 18,500 shares (reported as grant/award).
• Reported price/value: $0.00 on the Form 4 (typical for option grants; not an open-market purchase).
• Vesting: 100% vests on June 15, 2027 (one-year cliff), subject to continued service (footnote F1).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No indication of sale, exercise, tax withholding, or 10b5-1 plan in this filing.

Context This is a time‑based option grant to a director that does not involve an immediate market purchase or sale. The option vests in full one year after the grant; only upon vesting and any subsequent exercise or sale would there be a reportable purchase or sale affecting share count or value. Grants are common as compensation and do not by themselves indicate trading sentiment.